Physician profile
Tarun Mathur
NPI 1649259862
$7,302.53
in general payments reported to CMS, 2019-2025
33 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $714 · 2021: $1,143 · 2022: $1,521 · 2023: $1,006 · 2024: $784 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,644.98 | 2019-2025 | |
| Pfizer INC. | $1,086.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $637.77 | 2019-2022 | |
| Boston Scientific Corporation | $616.03 | 2019-2024 | Watchman Access System, Watchman, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $393.99 | 2019-2023 | |
| Amarin Pharma, INC. | $325.18 | 2019-2022 | |
| Amgen INC. | $286.26 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $246.38 | 2021-2024 | Camzyos, Eliquis |
| Atricure, INC. | $241.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $231.81 | 2019-2024 | Wainua |
| Impulse Dynamics (USA) INC. | $190.78 | 2022-2025 | Optimizer, Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $151.94 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.73 | 2019 | |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Genzyme Corporation | $115.67 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $112.76 | 2019 | |
| Optinose US, INC. | $110.90 | 2025 | |
| Abbvie INC. | $106.52 | 2022 | |
| Merck Sharp & Dohme LLC | $101.70 | 2023-2024 | Verquvo |
| Daiichi Sankyo INC. | $76.16 | 2024-2025 | Injectafer |
| Kiniksa Pharmaceuticals, Ltd. | $54.36 | 2022-2023 | Arcalyst |
| Preventice Services, LLC | $46.62 | 2020 | |
| Alnylam Pharmaceuticals INC. | $46.31 | 2024-2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $40.24 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.06 | 2023-2025 | Lifevest |
| Abiomed | $33.38 | 2025 | |
| Lilly USA, LLC | $30.57 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $19.27 | 2023 | Edarbyclor |
| Inspire Medical Systems, INC. | $19.14 | 2024 | Inspire |
| Scpharmaceuticals INC. | $16.48 | 2024 | |
| W. L. Gore & Associates, INC. | $13.56 | 2022 | |
| Lantheus Medical Imaging, INC. | $12.43 | 2019 | |
| Lundbeck LLC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.